To search broadly for potential vulnerabilities, the panel contained a diverse collection of compounds, including drugs targeted to the specific erlotinib-resistance-conferring T790M-EGFR mutation18, 19, 20, 21, kinase inhibitors affecting multiple cancer-related pathways and chemotherapy and epigenetic drugs. Here, EGFR is linked to cancer.